Cancer

Natural product-derived therapy for Acute Myeloid Leukemia: A therapeutic mix encompassing Ivermectin and Curcumin  decreases the expression of BCLAF1,  promotes differentiation of acute myeloid leukemic cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 28/August/2017, 12.23 am
Natural product-derived therapy for Acute Myeloid Leukemia: A therapeutic mix encompassing Ivermectin and Curcumin  decreases the expression of BCLAF1,  promotes differentiation of acute myeloid leukemic cells, restores treatment responsiveness, increases therapeutic index of anticancer drugs, and promotes regression of AML via up-regulation of its target gene, 28/August/2017, 12.23 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Institute of Genetics and Biophysics, CNR, Naples, Italy; and Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy…

read more

Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of metastasis/tumor suppressors  BTG2 and INK4a, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 27/August/2017, 8.25 am
Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of metastasis/tumor suppressors  BTG2 and INK4a, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 27/August/2017, 8.25 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Natural product-derived therapy for gynecologic cancers: A therapeutic mix encompassing  Berberine (BER), Dihydroartemisinin (DHA), and Curcumin (CUR)inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers via up-regulation of its target gene, 26/August/2017, 11.59 pm
Natural product-derived therapy for gynecologic cancers: A therapeutic mix encompassing  Berberine (BER), Dihydroartemisinin (DHA), and Curcumin (CUR)inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers via up-regulation of its target gene, 26/August/2017, 11.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA shows that “ARID1A-mutated ovarian cancers depend on HDAC6 activity” This study…

read more

Natural product-derived therapy for EVI-1-Overexpressing Acute Myeloid Leukemia: Dihydroartemisinin (DHA), isolated from Artemesia Annua L,  decreases the expression of MECOM/EVI-1 and its down target genes, including CKMT-1, alters Arginine-creatine metabolism, inhibits mitochondrial respiration, depletes ATP levels, and promotes regression of EVI-1-overexpressing AML via up regulation of its target gene, 26/August/2017, 12.56 pm
Natural product-derived therapy for EVI-1-Overexpressing Acute Myeloid Leukemia: Dihydroartemisinin (DHA), isolated from Artemesia Annua L,  decreases the expression of MECOM/EVI-1 and its down target genes, including CKMT-1, alters Arginine-creatine metabolism, inhibits mitochondrial respiration, depletes ATP levels, and promotes regression of EVI-1-overexpressing AML via up regulation of its target gene, 26/August/2017, 12.56 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; and Broad Institute of…

read more

Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: A therapeutic mix encompassing Berberine, Gambogic acid, β-Cryptoxanthin (BCX) [BGBCX]  increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via up regulation of its target gene, 25/August/2017, 5.20 am
Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: A therapeutic mix encompassing Berberine, Gambogic acid, β-Cryptoxanthin (BCX) [BGBCX]  increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via up regulation of its target gene, 25/August/2017, 5.20 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (1) Cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53…

read more

Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of tumor suppressors PDCD4 and PTEN, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 25/August/2017, 4.48 am
Molecular therapy for Metastatic cancers: Myrtenal, isolated  from Taxus, increases the expression of tumor suppressors PDCD4 and PTEN, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 25/August/2017, 4.48 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more
Start Typing